BIO's "Big Ideas" Include Expanding FDA's Mission, Allowing "Progressive Approval"
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA would no longer just be tasked with protecting public health but also with encouraging product development under ambitious legislative proposals that BIO is set to reveal.
You may also be interested in...
“Breakthrough Therapy”: New Pathway in FDASIA May Point The Way To Future Reforms
A new FDA designation process for “breakthrough” drugs is one of the few “innovation” features of the FDA Safety & Innovation Act. It is likely to be very attractive to biotech sponsors, though its impact on actual product approvals is uncertain at best. The real “breakthrough,” though, may be in the collaborative model that led to the legislation – and that is an important message for sponsors hoping for bigger reforms ahead.
Senior CDER Management Panel Could Facilitate Novel Therapy Approval
CDER Director Janet Woodcock is creating an executive-level forum to deliberate medical policies, including those needed to smooth drug reviews. She envisions stakeholder input on topics for discussion by the panel.
Senior CDER Management Panel Could Facilitate Novel Therapy Approval
CDER Director Janet Woodcock is creating an executive-level forum to deliberate medical policies, including those needed to smooth drug reviews. She envisions stakeholder input on topics for discussion by the panel.